Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30241803 | 0.84 | KIF11 (0.53) | KCNN4KMT2ARECQLMAPK1KIF11 | |
| SCHEMBL8939158 | 0.79 | KCNN4 (0.48) | KCNN4MAPTKMT2ANPSR1CYP1A2 | |
| SCHEMBL25848127 | 0.78 | MAPT (0.61) | KCNN4MAPTKMT2ACYP1A2CYP3A4 | |
| SCHEMBL14342915 | 0.77 | KCNN4 (0.47) | KCNN4MAPTKMT2ANPSR1CYP1A2 | |
| SCHEMBL13868873 | 0.77 | KCNN4 (0.47) | KCNN4MAPTKMT2ANPSR1CYP1A2 | |
| SCHEMBL13828216 | 0.77 | OPRM1 (0.55) | KCNN4MAPTKMT2ANPSR1CYP1A2 | |
| SCHEMBL13865461 | 0.77 | KCNN4 (0.47) | KCNN4MAPTKMT2ANPSR1CYP1A2 | |
| Hydrochloric Acid SCHEMBL29273297 | 0.77 | MAPT (0.59) | KCNN4MAPTKMT2ACYP1A2CYP3A4 | |
| SCHEMBL28393908 | 0.76 | CES1 (0.61) | KCNN4KMT2ANPSR1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL1251198 | 0.76 | KCNN4 (0.45) | KCNN4MAPTKMT2ANPSR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090699-A1 | FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-03-20 | — | — | US | disclosed |
| WO-2025037249-A1 | FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-02-20 | — | — | WO | disclosed |
| EP-4397673-A1 | COMPOUND AND LABELED BIOMATERIAL USING SAME | FUJIFILM Corporation (JP) | 2024-07-10 | — | — | EP | disclosed |
| EP-4397671-A1 | COMPOUND AND LABELED BIOMATERIAL USING SAME | FUJIFILM Corporation (JP) | 2024-07-10 | — | — | EP | disclosed |
| EP-4397672-A1 | COMPOUND AND LABELED BIOMATERIAL USING SAME | FUJIFILM Corporation (JP) | 2024-07-10 | — | — | EP | disclosed |
| US-20240182383-A1 | COMPOUND AND LABELED BIOLOGICAL SUBSTANCE USING THE SAME | FUJIFILM CORPORATION (JP) | 2024-06-06 | — | — | US | disclosed |
| US-20240173437-A1 | COMPOUND AND LABELED BIOLOGICAL SUBSTANCE USING THE SAME | FUJIFILM CORPORATION (JP) | 2024-05-30 | — | — | US | disclosed |
| US-20240165240-A1 | COMPOUND AND LABELED BIOLOGICAL SUBSTANCE USING THE SAME | FUJIFILM CORPORATION (JP) | 2024-05-23 | — | — | US | disclosed |
| CN-117642412-A | Compounds and labeled biological substances using the same | 富士胶片株式会社 | 2024-03-01 | — | — | CN | disclosed |
| CN-117642414-A | Compounds and labeled biological substances using the same | 富士胶片株式会社 | 2024-03-01 | — | — | CN | disclosed |
| CN-117642413-A | Compounds and labeled biological substances using the same | 富士胶片株式会社 | 2024-03-01 | — | — | CN | disclosed |
| WO-2023032996-A1 | COMPOUND AND LABELED BIOMATERIAL USING SAME | 富士フイルム株式会社 | 2023-03-09 | — | — | WO | disclosed |
| WO-2023032994-A1 | COMPOUND AND LABELED BIOMATERIAL USING SAME | 富士フイルム株式会社 | 2023-03-09 | — | — | WO | disclosed |
| WO-2023032995-A1 | COMPOUND AND LABELED BIOMATERIAL USING SAME | 富士フイルム株式会社 | 2023-03-09 | — | — | WO | disclosed |
| CN-108271357-B | Molecular constructs for treatment of transplant rejection | 免疫功坊股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182383-A1 | COMPOUND AND LABELED BIOLOGICAL SUBSTANCE USING THE SAME | SHBG, NR0B2, NR3C1 | KCNN4 2256/4885MAPT 4809/4885KMT2A 3205/4885 |
| US-20240173437-A1 | COMPOUND AND LABELED BIOLOGICAL SUBSTANCE USING THE SAME | OR10J3, NR2E3, NR0B2 | KCNN4 2691/4885MAPT 4310/4885KMT2A 3378/4885 |
| US-20240165240-A1 | COMPOUND AND LABELED BIOLOGICAL SUBSTANCE USING THE SAME | NR0B2, NR0B1, OR10J3 | KCNN4 2630/4885MAPT 4444/4885KMT2A 3444/4885 |
| US-20250090699-A1 | FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | FAP, FIBP, FGF23 | KCNN4 4846/4885MAPT 3257/4885KMT2A 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.